#VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity
In the phase 2 clinical trial of Eli Lilly’s retatrutide, the drug showed a notable weight reduction effect, with an average of 17.5% loss in body weight over a 24-week period. This investigational drug is distinctive in targeting GIP, GLP-1, and glucagon receptors, a novel approach compared to existing obesity treatments. The study, as reported in the New England Journal of Medicine, varied the dosages administered, noting the highest weight loss at the largest dosage.
Researchers recruited 338 adults who had a BMI over 30 or a BMI of 27–30 with one or more weight-related conditions and were assigned to one of the following experimental groups or a placebo group:
- 1 mg of subcutaneous retatrutide
- 4 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg
- 4 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg
- 8 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg
- 8 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg
- 12 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg
The trial’s promising results pave the way for further phase 3 research to evaluate retatrutide’s efficacy in comprehensive obesity management and its impact on associated health issues.
©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
